KPV

A short synthetic peptide fragment derived from α-MSH, researched for anti-inflammatory, tissue-repair, and gut-barrier support properties.

Typical bottle: 10 mg

Research note: Human evidence remains limited for many of KPV’s proposed applications, and much of the research remains preclinical, particularly around gut and barrier-tissue effects.

What It Is

KPV is a short synthetic peptide fragment derived from alpha-melanocyte-stimulating hormone (α-MSH), primarily researched for its anti-inflammatory, tissue-repair, and barrier-support properties.

KPV is particularly interesting because it focuses on regulating excessive inflammatory signaling rather than broadly suppressing the immune system. It has also received significant research attention in gut and intestinal health, where it has been studied for its potential effects on intestinal barrier integrity and inflammatory signaling.

Who May Benefit

Inflammation management
Muscle and tissue recovery
Gut and intestinal health
Intestinal barrier support
Recovery from physical stress
Chronic inflammatory conditions
Skin and barrier-tissue health
Tissue repair after injury

What to Expect

KPV is generally approached as a consistent anti-inflammatory and recovery-support compound rather than something expected to produce a dramatic immediate effect.

Some report improvements in inflammation-related discomfort, recovery, gut comfort, skin quality, and overall tissue resilience — these reports are anecdotal, and individual response varies.

What to Pair It With

BPC-157

A natural complement — BPC for tissue repair and angiogenesis, KPV for inflammatory regulation.

TB-500

Cell migration and tissue remodeling research pairs well with KPV’s inflammation focus.

Cartalax

Complementary for joint and structural-tissue research alongside KPV’s inflammation control.

GHK-Cu

Collagen production and tissue remodeling complement KPV’s barrier and inflammation research.

Reconstitution

Vial

10 mg

Diluent

1 mL Bac. Water

Final Concentration

10 mg/mL

5 units = 500 mcg10 units = 1 mg

Suggested Research Dosing Strategy

Standard / Lower Range

500 mcg (5 units)

Once daily · subcutaneous · 5–7× per week.

Advanced Range

1 mg (10 units)

Once daily · subcutaneous · 5–7× per week.

Suggested research cycle: 8–12 weeks ON, followed by approximately 2–4 weeks OFF. Estimated quantity for a complete cycle: approximately 2–4 × 10 mg vials.

Administration Notes

Subcutaneous administration is commonly used, in the morning or evening.

A fasted state may be incorporated into the research protocol. The abdomen is a common subcutaneous administration area.

Maintain appropriate sterile handling and storage practices.

Research Considerations

KPV is derived from α-MSH, but its research profile differs from the parent molecule — focused on inflammatory signaling rather than the broader effects of full-length α-MSH.

One area of particular interest is the gastrointestinal tract, where KPV has been investigated for its interaction with peptide transport systems and effects on intestinal inflammatory signaling and barrier integrity. It is frequently combined with BPC-157 since the two approach inflammation and repair through different mechanisms.

Have a specific question about KPV? Chat with Pulse, Signal IQ’s free AI research assistant — ask about mechanisms, stacking, or how it compares to other compounds.

For research purposes only. Not approved for human use. This information is provided for educational and research purposes and is not medical advice. Signal IQ does not sell peptides.

All Peptides by Goal